Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 105, Issue 4, 1997, Pages 187-195

  Nauck, M A ^a   Holst, J J ^b   Willms, B ^c   Schmiegel, W ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Fachklinik Diabet S   (Germany)

Author keywords

Glucagon; Glucagon like peptide 1 (GLP 1); Incretin hormones; Insulin; New therapy

Indexed keywords

ALPHA GLUCOSIDASE; ENPROSTIL; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; INSULIN; PROINSULIN; SULFONYLUREA;

FOOD INTAKE; HUMAN; INSULIN DEFICIENCY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERNUTRITION; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING;

EID: 0030983816     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211750     Document Type: Review

References (81)

1. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC: Exon duplication and divergence in the human proglucagon gene. Nature 304: 368-371, 1983
2. Brubaker PL: Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinol 128: 3175-3182, 1991
3. Chiasson J-L, Josse RG, Hunt JA, et al.: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled trial. Ann Intern Med 121: 928-935, 1994
4. Coniff RF, Seaton TB, Shapiro JA, Beisswenger P, Robbins D, McGill JB, Kleinfield R: Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM, Diabetes Care 18: 817-824, 1995
5. Creutzfeldt W, Kleine N, Willms B, Ørskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycaemia by exogenous glucagon-like peptide 1 [7-36 amide] in type 1 (insulin-dependent)-diabetic patients. Diabetes Care 19: 580-586, 1996
6. Creutzfeldt W, Nauck M: Gut hormones and diabetes mellitus. Diabetes Metab Rev 8: 149-177, 1992
7. 2-terminus in type 2 diabetic patients and in healthy subjects. Diabetes 44: 1126-1131, 1995
8. DeFronzo RA: The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM, Diabetes 37: 667-687, 1988
9. The Diabetes Control and Complications Trial Research Group: Hypoglycaemia in the diabetes control and complications trial. Diabetes 46: 271-286, 1997
10. Dupré J, Behme MT, Hramiak IM, McDonald TJ: Subcutaneous glucagon-like peptide 1 combined with insulin normalizes postcibal glycemic excursions in IDDM, Diabetes Care 20: 381-384, 1997
11. Dupré J, Behme MT, Hramiak M, McFarlane P, Williamson MP, Zabel P, McDonald TJ: Glucagon-like peptide 1 reduces postprandial glycemic excursions in IDDM, Diabetes 44: 626-630, 1995
12. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Göke B: Glucagon-like peptide 1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22: 283-291, 1992
13. Elahi D, McAllon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK: The insulinotropic actions of glucose-dependend insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul. Pept. 51: 63-74, 1994
14. Fehmann H-C, Habener HF: Insulinotropic hormone glucagon-like peptide-1 (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells. Endocrinol 130: 159-166, 1992
15. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA: Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type 2 diabetes mellitus. Gastroenterol 109: 755-765, 1995
16. Fukase N, Takahashi H, Manaka H et al.: Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion. Diabetes Res Clin Pract 15: 187-195, 1992
17. Gerich JE: Abnormal glucagon secretion in type 2 (noninsulin-dependent) diabetes mellitus: causes and consequences. In: Creutzfeldt W. Lefèbvre P, (eds.). Diabetes mellitus: Pathophysiology and therapy. pp. 127-133, Springer Verlag Berlin Heidelberg. 1989
18. Göke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, Kleist P, Arnold R, Lücker PW: Voglibose (AO-128) is an efficient α-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 56: 493-501, 1995
19. Göke R, Fehmann H-C, Linn T, Schmidt H, Krause M, Eng J, Göke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem 268: 19650-19655, 1993a
20. Göke R, Wagner B, Fehmann H-C, Göke B: Glucose-dependency of the insulin-stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med 193: 97-103, 1993b
21. Gray GM: Carbohydrate digestion and absorption. Gastroenterol 58: 96-107, 1970
22. Gutniak M, Larson H, Heiber SJ, Juneskans OT, Holst JJ, Ahrén B: Potential therapeutic levels of glucagon-like peptide 1 achieved in humans by a buccal tablet. Diabetes Care 19: 843-848, 1996
23. Gutniak MK, Linde B, Holst JJ, Efendic S: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM, Diabetes Care 17: 11039-1044, 1994
24. Gutniak M, Ørskov C, Holst JJ, Åhren B, Efendic S: Anti-diabetogenic effect of glucagon-like peptide-1 [7-36 amide] in normal subjects and patients with diabetes. N Engl J Med 326: 1316-1322, 1992
25. Hanefeld M, Fischer S, Schulze J, Spengler M, Wargenau M, Schollberg K, Fücker K: Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 14: 732-737, 1991
26. Hargrove DM, Nardone NA, Persson LM, Parker JC, Stevenson RW: Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short-or long-term administration. Metabolism 44: 1231-1237, 1995
27. Hayakawa T, Kondo T, Okumura N, Nagai K, Shibata T, Kitigawa M: Enteroglucagon release in disaccharide malabsorption induced by intestinal α-glucosidase inhibition. Am J Gastroenterol 84: 523-526, 1989
28. Herrmann C, Vöge A, Göke B: Regulation of glucagon-like peptide release from the isolated perfused rat ileum by nutrients, peptides and neuromediators. Digestion 54: 367, 1993
29. Hoffmann J, Spengler M: Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen study. Diabetes Care 17: 561-566, 1994
30. Holst JJ, Ørskov C, Vagn Nielsen O, Schwartz TW: Truncated glucagon-like peptide 1 an insulin-releasing hormone from the distal gut. FEBS Letters 211: 169-174, 1987
31. Johnson OFL, Cleleand JL, Lee HJ, Charnis M, Duenas E, Jaworowicz W, Shepard D, Shahzamani A, Jones AJS, Putney SD: A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med 2: 795-799, 1996
32. Juntii-Berggren L, Pigon J, Karpe F, Hamsten A, Gutniak M, Vignati L, Efendic S: The antidiabetogenic effect of GLP-1 is mainatined during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 19: 1200-1206, 1996
33. Kawai K, Suzuki S, Ohashi S, Mukai H, Ohmori H, Murayama Y, Yamashita K: Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from the isolated perfused canine and rat pancreases. Endocrinol 124: 1768-1773, 1989
34. Kolligs F, Fehmann H-C, Göke R, Göke B: Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44: 16-19, 1995
35. Kreymann B, Ghatei MA, Williams G, Bloom SR: Glucagon-like peptide 1 7-36: a physiological incretin in man. Lancet II: 1300-1304, 1987
36. Larsen J, Jallad N, Damsbo P: One-week continous infusion of GLP-1 (7-37) improves the glycaemic control in NIDDM (abstract). Diabetes 45 (Suppl. 2): 233 A, 1996
37. Layer P, Holst JJ, Grandt D, Goebell H: Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dia Dis Sci 40: 1074-1082, 1995
38. Lembcke B, Fölsch UR, Caspary WF, Eben R, Creutzfeldt W: Influence of metronidazole on the breath hydrogen response and symptoms in acarbose-induced malabsorption of sucrose. Digestion 25: 186-193, 1983
39. Lopez LC, Frazier ML, Su C-J, Kumar A, Saunders GF: Mammalian pancreatic proglucagon contains three glucaaon-related peptides. Proc Natl Acad Sci USA 80: 5485-5489, 1983
40. Mathiowitz E, Jacob JS, Jong YS, Carino GP, Chickering DE, Chaturvedi P, Santos CA, Vijayaraghavan K, Montgomery S, Bassett M, Morell C: Biologicallly erodable microspheres as potential oral drug delivery systems. Nature 386: 410-414, 1997
41. May C: Wirksamkeit und Verträglichkeit von einschleichend dosierter Acarbose bei Patienten mit nichtinsulinpflichtigem Diabetes mellitus (Typ-II-Diabetes) unter Sulfonylharnstofftherapie. Diabetes Stoffw 4: 3-8, 1995
42. Nakabayashi M, Nishizawa M, Nakagawa A, Takeda R, Nijima A: Vagal hepatopancreatic reflex evoked by intraportal appearance of GLP-1. Am J Physiol 271: E 808-813, 1996
43. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagon-like peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15: 270-276, 1992
44. Nauck M, Bartels E, Ørskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological insulinotropic hormone and alucose concentrations. J Clin Endocrinol Metab 76: 912-917, 1993a
45. Nauck MA, Ettler R, Niedereichholz U, Ørskov C, Holst JJ, Schmiegel W: Inhibition of gastric emptying by GLP-1 [7-36 amide] or [7-37]: effects on postprandial glycaemia and insulin secretion (abstract). Gut 37 (Suppl 2): A 124, 1995
46. 2 on glucose tolerance and on the secretion of pancreatic and gastrointestinal hormones in man. Eur J Clin Invest 19: 298-305, 1989
47. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 (GLP-1) [7-36 amide] but not of synthetic human gastric inhibitory polypeptide (GIP) in patients with Type 2 diabetes mellitus. J Clin Invest 91: 301-307, 1993b
48. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744, 1993c
49. Nauck MA, Wollschläger D, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Willms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with type 2-diabetes Diabetologia; 39: 1546-1553, 1996
50. Nicholl CG, Carolan G, Sevelius H, Bloom SR: Effect of enprostil on gastric emptying, intestinal transit time and post-prandial release of gastro-intestinal peptides. Digestion 43: 47-55, 1989
51. Ohlson L-O, Larsson B, Svärdsudd K, Welin L, Eriksson H, Wilhelmsen L, Björntorp P, Tibblin G: The influence of body fat distribution on the incidence of diabetes mellitus. Diabetes 34: 1055-1058, 1985
52. Ørskov C: Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35: 701-711, 1992
53. Ørskov C, Bersani M, Johnsen AH, Højrup P, Holst JJ: Complete sequences of glucagon-like peptide 1 from human and pig small intestine. J Biol Chem 264: 12826-12829, 1989
54. Ørskov C, Holst, JJ: Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 47: 165-174, 1987
55. Ørskov C, Holst JJ, Nielsen OV: Effect of truncated glucagon-like peptide-1 (proglucagon 78-101 amide) on endocrine secretion from pig pancreas, antrum and non-antral stomach. Endocrinology 23: 2009-2013, 1988
56. Ørskov C, Holst JJ, Seier Poulsen S, Kirkegaard P: Pancreatic and intestinal processing of proslucagon in man. Diabetologia 30: 874-881, 1987
57. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43: 535-539, 1994
58. Ørskov L, Holst J, Møller J, Ørskov C, Møller N, Alberti KGMM, Schmitz O: GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39: 1227-1232, 1996
59. Qualmann C, Nauck M, Holst JJ, Ørskov C, Creutzfeldt W: Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 32: 13-16, 1995a
60. Qualmann Ch. Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W: Glucagon-like peptide 1 (GLP-1) [7-36 amide] secretion in response to luminal sucrose from the upper and lower gut. A study using α-glucosidase inhibition (acarbose). Scand J Gastroenterol 30: 892-896, 1995b
61. Rachman J, Barrow BA, Levy JC, Turner RC: Near-normalisation of diurnal glucose concentrations by continous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205-211, 1997
62. Rahier J, Goebbels RM, Henquin JC: Cellular composition of the human diabetic pancreas. Diabetologia 24: 366-371, 1983
63. Rahier JRD, Ibrahim M, Channaoui K: Islet cell populations in obese subjects and Type 2 (non-insulin-dependent) diabetic patients. (abstract). Diabetologia 32: 532 A, 1989
64. Reaven GM, Swislocki ALM, Jeng CY, Hollenbeck CB, Schwartz K, Chen Y-DI: Effect of enpostil on plasma glucose, insulin and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Horm. Metabol. Res. 20: 633-636, 1988
65. Ritzel R, Holst JJ, Ørskov C, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38: 720-725, 1995
66. Roberge JN, Brubaker PL: Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinol 128: 3169-3174, 1991
67. Sasaki H, Manaka H, Yamatani K, Tominaga M: GLP-1 secretion coupled with Na/glucose transporter from the isolated perfused canine ileum. Digestion 54: 365-367, 1993
68. Schatz H, for the "Ausschuß Pharmakotherapie des Diabetes mellitus": Zur klinischen Wirksamkeit und Zweckmäßigkeit von Acarbose und Metformin in der Therapie des Diabetes mellitus. Diabetes Stoffw 4: 407-421, 1995
69. Scrocchi LA, Brown TJ, Maclusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Medicine 2: 1254-1258, 1996
70. Toft-Nielsen M, Madsbad S, Holst JJ: The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45: 552-556, 1996
71. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucaaon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72, 1996
72. Uttenthal LO, Ukponmwan OO, Ghiglione M, Bloom SR: Acute and short term effects of intestinal alpha-glucosidase inhibition on gut hormone responses in man. Dia Dis Sci 32: 139-144, 1987
73. Vaiverde I, Villanueva-Peñacarillo ML: Target tissues for GLP-1 (7-36 amide). Digestion 54: 343, 1993
74. Varndell IM, Bishop AE, Sikri KL, Uttenthal LO, Bloom SR, Polak JM: Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microsopic immunocytochemistry. J Histochem Cytochem 33: 1080-1086, 1985
75. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR: Glucagon-like peptide-1 is a physiological incretin in the rat. J Clin Invest 95: 417-421, 1995
76. Ward WK, Beard JC, Porte D: Clinical aspects of islet B-cell function in non-insulin-dependent diabetes mellitus. Diabetes/Metabolism Rev 2: 297-313, 1986
77. Weber I, Bach-Esser A-K, Bach I, Richter S, Ørskov C, Holst JJ, Schmiegel W, Nauck MA: Prolonged normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2-diabetic patients (abstract). Diabetologia 38 (Suppl. 1): A 171, 1995
78. Wettergen A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ, Truncated GLP-1 (proglucagon 87-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38: 665-673, 1993
79. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide 1 (GLP-1) [7-36 amide] in Type 2 (non-insulin-dependent) diabetic patients. J Clin Endocrinol Metab 81: 327-332, 1996
80. Wrighton NC, Farrell FX, Chang R, Kashyab AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett RW, Jolliffe LK, Dower WJ, Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273: 458-463, 1996
81. Yki-Järvinen H: Role of insulin resistance in the pathogenesis of NIDDM, Diabetologia 38: 1378-1388, 1995